Close

RBC Capital Remains Bullish on AcelRx Pharma (ACRX) Following Positive SAP302 Trial

August 16, 2016 8:04 AM EDT Send to a Friend
RBC Capital reiterated an Outperform rating and $6.00 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following the company's SAP302 trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login